This inventor holds 3 USPTO granted patents. Top assignees: Fujisawa Pharmaceutical Company, Ltd., Morishita Jintan Co., Ltd.. Active years: 1987-1995.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Kyogo, JP (1987)
- Toyonaka, JP (1992)
- Takaoka, JP (1995)
Company Filing History:

Years Active: 1987-1995
Title: The Innovations of Nobuto Kanagawa
Introduction
Nobuto Kanagawa is a notable inventor based in Toyonaka, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of ointments and cyclic peptides. With a total of 3 patents to his name, Kanagawa's work has had a meaningful impact on the treatment of various skin diseases and allergic conditions.
Latest Patents
One of Kanagawa's latest patents is an ointment containing FK-506 or its derivatives. This ointment comprises a tricyclic compound, specifically FK 506, which is useful for treating various skin diseases. Another significant patent is the preparation of FR115224 substrate for parenteral administration. This cyclic peptide, designated FR115224, is administered parenterally in a cyclodextrin carrier and exhibits antiallergic activity.
Career Highlights
Throughout his career, Nobuto Kanagawa has worked with prominent companies in the pharmaceutical industry, including Fujisawa Pharmaceutical Company, Ltd. and Morishita Jintan Co., Ltd. His experience in these organizations has contributed to his expertise in developing innovative treatments.
Collaborations
Kanagawa has collaborated with several professionals in his field, including Sotoo Asakura and Takehisa Hata. These collaborations have likely enhanced his research and development efforts, leading to his successful patent applications.
Conclusion
Nobuto Kanagawa's contributions to pharmaceutical innovations demonstrate his commitment to improving healthcare through his inventions. His patents reflect a dedication to addressing significant medical challenges, particularly in dermatology and allergy treatment.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile